Andrew M Wardley
University of Manchester
171 Papers
799 Citations
Andrew M Wardley is an academic researcher from University of Manchester. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 162 publications. Previous affiliations of Andrew M Wardley include Manchester Academic Health Science Centre & University Hospital of South Manchester NHS Foundation Trust.
Chat about Author
Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. William Audeh,Jeffrey N. Weitzel,Michael Friedlander,Banu Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,James Carmichael +14 more
TL;DR: Findings from this phase 2 study provide positive proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.
2.3K
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. W. Audeh,J. N. Weitzel,Michael Friedlander,B. K. Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,J. Carmichael +14 more
TL;DR: The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCa1-associated orBRCA2-associated DNA repair.
1.6K
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian E. Smith,Marion Procter,Richard D. Gelber,Sebastien Guillaume,A. Feyereislova,Mitch Dowsett,Aron Goldhirsch,Michael Untch,Gabriella Mariani,José Baselga,Manfred Kaufmann,David Cameron,Richard Bell,Jonas Bergh,Robert E. Coleman,Andrew M Wardley,Nadia Harbeck,Roberto Ivan Lopez,Peter Mallmann,Karen A. Gelmon,Nicholas Wilcken,Erik Wist,Pedro Sánchez Rovira,Martine Piccart-Gebhart +23 more
TL;DR: The results show that 1 year of treatment with trastuzumab after adjuvant chemotherapy has a significant overall survival benefit after a median follow-up of 2 years, and the emergence of this benefit after only 2 years reinforces the importance of trastizumab in the treatment of women with HER2-positive early breast cancer.
1.6K
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Beat Thürlimann,Aparna Keshaviah,Alan S. Coates,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Manuela Rabaglio,Ian E. Smith,Andrew M Wardley,Karen N. Price,Aron Goldhirsch +13 more
TL;DR: In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites.
1.6K
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
Alan S. Coates,Aparna Keshaviah,Beat Thürlimann,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Marco Colleoni,István Láng,Lucia Del Mastro,Ian E. Smith,Jacquie Chirgwin,J.M. Nogaret,Tadeusz Pienkowski,Andrew M Wardley,Erik Jakobsen,Karen N. Price,Aron Goldhirsch +19 more
TL;DR: The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
948